Cartesian Therapeutics (RNAC) Stock Price, News & Analysis

Company Overview

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Key Stats

• Today's Range: $16.85 to $18.20
• 50-Day Range: $14.87 to $24.52
• 52-Week Range: $11.66 to $42.60
• Volume: 114,380 shs
• Average Volume: 117,810 shs
• Market Capitalization: $430.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $42.33
• Consensus Rating: Moderate Buy

Cartesian Therapeutics Stock Analysis - MarketRank™

Cartesian Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 583rd out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cartesian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Cartesian Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cartesian Therapeutics are expected to decrease in the coming year, from $4.07 to ($3.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cartesian Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cartesian Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cartesian Therapeutics has a P/B Ratio of 564.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.19% of the float of Cartesian Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cartesian Therapeutics has a short interest ratio ("days to cover") of 20.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Cartesian Therapeutics has recently decreased by 0.52%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cartesian Therapeutics does not currently pay a dividend.

Dividend Growth

Cartesian Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.19% of the float of Cartesian Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cartesian Therapeutics has a short interest ratio ("days to cover") of 20.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Cartesian Therapeutics has recently decreased by 0.52%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.8 / 5
• News Sentiment: -0.54

News Sentiment

Cartesian Therapeutics has a news sentiment score of -0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Cartesian Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for RNAC on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Cartesian Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 5.0 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Cartesian Therapeutics insiders have bought 17.63% more of their company's stock than they have sold. Specifically, they have bought $1,909,030.00 in company stock and sold $1,622,962.00 in company stock.

Percentage Held by Insiders

57.90% of the stock of Cartesian Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

86.95% of the stock of Cartesian Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RNAC Stock Analysis - Frequently Asked Questions

How have RNAC shares performed this year?

Cartesian Therapeutics' stock was trading at $20.6820 at the start of the year. Since then, RNAC stock has decreased by 18.1% and is now trading at $16.94.
View the best growth stocks for 2024 here.

How were Cartesian Therapeutics' earnings last quarter?

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) released its earnings results on Thursday, August, 8th. The company reported $0.54 EPS for the quarter, topping the consensus estimate of ($0.81) by $1.35. The company had revenue of $33.45 million for the quarter, compared to the consensus estimate of $6 million.

When did Cartesian Therapeutics' stock split?

Cartesian Therapeutics shares reverse split on the morning of Friday, April 5th 2024. The 1-30 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are Cartesian Therapeutics' major shareholders?

Cartesian Therapeutics' top institutional investors include FMR LLC (11.22%), Great Point Partners LLC (0.79%), State Street Corp (0.62%) and Geode Capital Management LLC (0.53%). Insiders that own company stock include Metin Kurtoglu and Milos Miljkovic.
View institutional ownership trends.

How do I buy shares of Cartesian Therapeutics?

Shares of RNAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Cartesian Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cartesian Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/06/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RNAC
• Previous Symbol: NASDAQ:RNAC
• CUSIP: N/A
• CIK: 1453687
• Web: selectabio.com
• Phone: 617-923-1400
• Fax: 617-924-3454
• Employees: 37
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $42.33
• High Stock Price Target: $50.00
• Low Stock Price Target: $39.00
• Potential Upside/Downside: +149.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($52.8320)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-219,710,000.00
• Net Margins: -510.72%
• Pretax Margin: -550.35%
• Return on Equity: N/A
• Return on Assets: -6.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.70
• Quick Ratio: 10.70

Sales & Book Value

• Annual Sales: $26 million
• Price / Sales: 16.56
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($82.38) per share
• Price / Book: -0.21

Miscellaneous

• Outstanding Shares: 25,420,000
• Free Float: 10,700,000
• Market Cap: $430.61 million
• Optionable: Optionable
• Beta: 0.63